LFG
HUMA icon

Larson Financial Group’s Humacyte HUMA Stock Holding History

Larson Financial Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Hold
12
– – ﹤0.01% 3612
2025
Q4 		$12 Hold
12
– – ﹤0.01% 3423
2025
Q3 		$21 Buy
+12
New +$24 ﹤0.01% 3393

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Larson Financial Group's HUMA Position: Q1 2026 in Review

Larson Financial Group held its Humacyte (HUMA) position steady in Q1 2026 at 12 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #3612.

Larson Financial Group first reported a position in HUMA in Q3 2025 and has held it in 3 quarters since. The position peaked at $21 in Q3 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Larson Financial Group held 12 shares of Humacyte worth $7 as of Q1 2026.
  • Larson Financial Group left its Humacyte share count unchanged in Q1 2026.
  • Humacyte made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3612 holding.
  • Larson Financial Group first reported a position in Humacyte in Q3 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Humacyte position peaked at $21 in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.